

SPEAKER SESSIONS

Saturday, 29 October 2016

SHORT COURSE

14:00 - 18:00	<p>Patient Registries Short Course</p> <p>OBSERVATIONAL DATA METHODS</p> <p>Larson L, Vinken A, Leatham O</p>
----------------------	---

Monday, 31 October 2016

PODIUM PRESENTATIONS

11:15 - 11:30	<p>Breakouts – Session I (MO1)</p> <p>ACHIEVING OPTIMAL FIT-TO-SURVIVAL DATA USING CUBIC SPLINE MODELS: A CASE-STUDY COMPARING THE FIT OF STANDARD AND CUBIC SPLINE MODELS TO SURVIVAL DATA FROM THE ICON6 STUDY</p> <p>Hettle R, Sackeyfio A, Suri G</p>
17:15 - 17:30	<p>Breakout – Session IV (AD2)</p> <p>A FRAMEWORK FOR MEASURING ADHERENCE TO MULTIPLE MEDICATIONS</p> <p>Pednekar P, Agh T, Malmenas M, Peterson AM</p>

POSTER SESSIONS

SESSION I

<p>DISPLAY HOURS: 8:45 – 14:15</p> <p>DISCUSSION: 13:15 – 14:15</p>	<p>PRM91</p> <p>REVIEW OF HEALTH ECONOMIC MODELS FOR ANTIBIOTICS</p> <p>Virhage M, Polyzoi M, Geale K, Geale K, Corcoran K, Anell B</p>
<p>DISPLAY HOURS: 8:45 – 14:15</p> <p>DISCUSSION: 13:15 – 14:15</p>	<p>PRM98</p> <p>EXTRAPOLATION WITH PATIENT LEVEL TIME-TO-EVENT DATA IN VARIOUS DISEASE AREAS: A REVIEW OF CURRENT RECOMMENDATIONS AND GAPS</p> <p>Kamra S, Kaur J, Kartheek J, Sehgal M, Siddiqui MK</p>
<p>DISPLAY HOURS: 8:45 – 14:15</p> <p>DISCUSSION: 13:15 – 14:15</p>	<p>PRM109</p> <p>TREATMENT EFFICACY IN SEQUENCE MODELLING</p> <p>A REVIEW OF PUBLISHED APPROACHES</p> <p>Polyzoi M, Medin E</p>
<p>DISPLAY HOURS: 8:45 – 14:15</p> <p>DISCUSSION: 13:15 – 14:15</p>	<p>PRM123</p> <p>INVESTIGATING THE IMPLEMENTATION OF ADVERSE EVENTS IN ECONOMIC MODELS: A SYSTEMATIC LITERATURE REVIEW IN MULTIPLE SCLEROSIS AND HUMAN IMMUNODEFICIENCY VIRUS</p> <p>Gillies H, Polyzoi M, Medin E</p>

DISPLAY HOURS: 8:45 – 14:15 DISCUSSION: 13:15 – 14:15	PIN89 ESTIMATING THE VALUE OF A NEW ANTIBIOTIC: A NOVEL APPROACH USING ESBL AS A CASE STUDY Geale K, Geale K, Corcoran K, Virhage M, Anell B
<i>SESSION II</i>	
DISPLAY HOURS: 15:45 – 19:45 DISCUSSION: 18:45 – 19:15	WHAT EU MEAN TO THE MHRA! POTENTIAL IMPACT OF ‘BREXIT’ ON PHARMACEUTICAL REGULATION IN THE UK Macaulay R, Attri S, Pandey V, Ahuja A
DISPLAY HOURS: 15:45 – 19:45 DISCUSSION: 18:45 – 19:15	PHP41 THE UK EARLY ACCESS TO MEDICINES SCHEME: A 2-YEAR STATUS UPDATE ON SUCCESSES, ISSUES AND CONTROVERSIES Macaulay R
DISPLAY HOURS: 15:45 – 19:45 DISCUSSION: 18:45 – 19:15	PHP47 THE FUTURE OF UK DRUG PRICING: THE 2014 PPRS (AN INTERIM REVIEW) Macaulay R
DISPLAY HOURS: 15:45 – 19:45 DISCUSSION: 18:45 – 19:15	PHP278 CADTH’S \$50,000 COST-EFFECTIVENESS THRESHOLD: FACT OR FICTION? Griffiths EA, Vadlamudi NK
DISPLAY HOURS: 15:45 – 19:45 DISCUSSION: 18:45 – 19:15	PHP282 NICE’S CRITERIA FOR END-OF-LIFE THERAPIES: IS THERE A FOURTH HURDLE TO OVERCOME? Griffiths EA
DISPLAY HOURS: 15:45 – 19:45 DISCUSSION: 18:45 – 19:15	PHP286 PRODUCTS OUTSIDE THE GENERAL REIMBURSEMENT SYSTEMS – A SWEDISH AND NORWEGIAN COMPARISON Dibbern T, Corcoran K, Medin E
DISPLAY HOURS: 15:45 – 19:45 DISCUSSION: 18:45 – 19:15	PHP296 SWEDISH PERSPECTIVE ON HEALTH TECHNOLOGY ASSESSMENTS WITH INCREMENTALLY LOWER COSTS AND EFFECTS Geale K, Geale K, Dibbern T, Virhage M, Medin E, Medin E
DISPLAY HOURS: 15:45 – 19:45 DISCUSSION: 18:45 – 19:15	PHP300 IS THERE EVIDENCE OF A DIFFERENCE BETWEEN WILLINGNESS TO PAY AND WILLINGNESS TO ACCEPT THRESHOLDS? A REVIEW OF NICE TECHNOLOGY APPRAISALS Minacori R, Geale K
DISPLAY HOURS: 15:45 – 19:45 DISCUSSION: 18:45 – 19:15	PHP353 COULD AMNOG BECOME IRRELEVANT IN THE 21ST CENTURY? POTENTIAL REDUNDANCIES IN THE AMNOG PROCESS IN THE ERA OF CURATIVE THERAPIES Macaulay R
DISPLAY HOURS: 15:45 – 19:45 DISCUSSION: 18:45 – 19:15	PHP372 MANAGED ACCESS AGREEMENTS: A NEW MODEL PATHWAY FOR THE REIMBURSEMENT OF NON-ONCOLOGY DRUGS IN ENGLAND APPROVED UNDER EUROPEAN ADAPTIVE PATHWAYS? Macaulay R

DISPLAY HOURS:
15:45 – 19:45
DISCUSSION:
18:45 – 19:15

PUK11

ESTIMATING THE ECONOMIC AND CLINICAL BENEFITS OF MIRABEGRON VERSUS ANTIMUSCARINICS FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) IN THE UNITED KINGDOM (UK)

Nazir J, Berling M, McCrea C, Fatoye F, Hakimi Z, Wagg A

Tuesday, 1 November 2016

PODIUM PRESENTATIONS

9:00 - 9:15

Breakout – Session V (ND2)

ADVANCED PARKINSON'S DISEASE IN STOCKHOLM COUNTY, SWEDEN
HOW MANY ARE THEY AND WHAT ARE THE REAL-LIFE HEALTH CARE COSTS?

Eriksson JK, Anell B

16:30 - 16:45

Breakout – Session VIII (MD1)

MEDICAL DEVICES: TIMELY ACCESS AND REIMBURSEMENT
CAN NATIONAL HEALTH TECHNOLOGY ASSESSMENT BODIES BE PART OF THE SOLUTION?

Macaulay R, Shaw S

POSTER SESSIONS

SESSION III

DISPLAY HOURS:
8:45 – 13:45
DISCUSSION:
12:45 – 13:45

PRS31

COST-EFFECTIVENESS OF ADDING BEDAQUILINE TO BACKGROUND DRUG REGIMENS FOR THE TREATMENT OF MULTIDRUG-RESISTANT AND EXTENSIVELY-RESISTANT TUBERCULOSIS IN ITALY

Codecasa LR, Toumi M, D'Ausilio A, Aiello A, Da Mele F, Termini R, Uglietti A, Hettle R, Graziano G, De Lorenzo S

DISPLAY HOURS:
8:45 – 13:45
DISCUSSION:
12:45 – 13:45

PRS46

COST-EFFECTIVENESS ANALYSIS OF SELEXIPAG VERSUS INHALED ILOPROST IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN SWEDEN

Włodarczyk J, Hunsche E, Silberberg B, Kemp D, Anell B, Corcoran K, Minacori R, Stevenson M, Beaudet A

DISPLAY HOURS:
8:45 – 13:45
DISCUSSION:
12:45 – 13:45

PSY23

THE PREVALENCE OF PLAQUE PSORIASIS, PSORIATIC ARTHRITIS AND THE OVERLAP BETWEEN THEM IN NORWAY

Polyzoi M, Virhage M, Geale K, Anell B

DISPLAY HOURS:
8:45 – 13:45
DISCUSSION:
12:45 – 13:45

PSY75

COST-EFFECTIVENESS OF ADDING NOVEL OR GROUP 5 INTERVENTIONS TO A BACKGROUND REGIMEN FOR THE TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS IN GERMANY

Wirth D, Dass R, Hettle R

SESSION IV

DISPLAY HOURS:
15:15 – 19:15
DISCUSSION:
18:15 – 19:15

PDB53

A SYSTEMATIC LITERATURE REVIEW TO IDENTIFY CLINICAL DRIVERS IN COST-EFFECTIVENESS ANALYSES IN T2DM PATIENTS UNCONTROLLED ON CURRENT THERAPIES

Afonso M, Gupta J, Kamra S, Jasso-Mosqueda J

POSTER SESSIONS

SESSION V

<p>DISPLAY HOURS: 8:45 – 13:45 DISCUSSION: 12:45 – 13:45</p>	<p>Breakouts – Session I (MO1) ACHIEVING OPTIMAL FIT-TO-SURVIVAL DATA USING CUBIC SPLINE MODELS: A CASE-STUDY COMPARING THE FIT OF STANDARD AND CUBIC SPLINE MODELS TO SURVIVAL DATA FROM THE ICON6 STUDY Hettle R, Sackeyfio A, Suri G</p>
<p>DISPLAY HOURS: 8:45 – 13:45 DISCUSSION: 12:45 – 13:45</p>	<p>Breakout – Session IV (AD2) A FRAMEWORK FOR MEASURING ADHERENCE TO MULTIPLE MEDICATIONS Pednekar P, Agh T, Malmenas M, Peterson AM</p>
<p>DISPLAY HOURS: 8:45 – 13:45 DISCUSSION: 12:45 – 13:45</p>	<p>PMD94 COMPARATIVE EXPLORATORY ANALYSIS ON EFFECTIVENESS, TOLERABILITY AND PATIENT/NURSE SATISFACTION WITH TWO NON-INVASIVE PATIENT CONTROLLED ANALGESIA TREATMENTS FOR ACUTE POST-OPERATIVE PAIN MANAGEMENT Katz P, Takyar S, Palmer PP, DiDonato K, Liedgens H</p>
<p>DISPLAY HOURS: 8:45 – 13:45 DISCUSSION: 12:45 – 13:45</p>	<p>PCN17 THE EFFECT OF POOLING VERSUS SEPARATING STANDARD CHEMOTHERAPIES IN THE MIXED TREATMENT COMPARISON OF CEDIRANIB VERSUS BEVACIZUMAB IN PLATINUM SENSITIVE RELAPSED OVARIAN CANCER Sackeyfio A, Gupta P, Siddiqui K</p>
<p>DISPLAY HOURS: 8:45 – 13:45 DISCUSSION: 12:45 – 13:45</p>	<p>PCN126 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN SWEDEN Baker TM, Paly VF, Thybo S, Hultberg M, Minacori R, Kotapati S, Sabater J</p>
<p>DISPLAY HOURS: 8:45 – 13:45 DISCUSSION: 12:45 – 13:45</p>	<p>PCN128 USE OF NET MONETARY BENEFIT ANALYSIS TO COMPREHENSIVELY UNDERSTAND THE VALUE OF INNOVATIVE TREATMENTS Shafrin J, May SG, Skornicki M, Hathway J, Macaulay R, Villeneuve J, Lees M, Hertel N, Penrod JR, Jansen J</p>
<p>DISPLAY HOURS: 8:45 – 13:45 DISCUSSION: 12:45 – 13:45</p>	<p>PCN192 HEALTHCARE RESOURCE UTILIZATION (HCRU) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): COMPARISON OF EU AND US COHORTS IN THE PREAMBLE STUDY Vij R, Zyczynski T, Daumont M, Popov S, Davis C, Zagorska A, Goldschmidt H</p>
<p>DISPLAY HOURS: 8:45 – 13:45 DISCUSSION: 12:45 – 13:45</p>	<p>PCN199 ASSESSING THE IMPACT OF CEDIRANIB ON THE HEALTH STATE UTILITY OF PATIENTS WITH PLATINUM SENSITIVE RELAPSED OVARIAN CANCER Hettle R, Sackeyfio A, Konings P, Malmenas M</p>
<p>DISPLAY HOURS: 8:45 – 13:45 DISCUSSION: 12:45 – 13:45</p>	<p>PCN203 A REVIEW OF HEALTH STATE UTILITY VALUES USED IN UK NICE APPRAISALS IN ADVANCED NSCLC Dansk V, Large S, Bertranou E, Bodnar C, Dyer MT, Ryan J</p>
<p>DISPLAY HOURS: 8:45 – 13:45 DISCUSSION: 12:45 – 13:45</p>	<p>PCN316 REVIEW OF CLINICAL PRACTICE GUIDELINES AND TREATMENT PATTERNS IN METASTATIC PANCREATIC CANCER IN EU-5 COUNTRIES Kalra M, Singh B, Ahuja A, Sharma S</p>

13:45 – 14:45	<p>W30</p> <p>MEASURING MULTIPLE MEDICATION ADHERENCE – WHICH MEASURE WHEN?</p> <p>Priti Pednekar, Tamas Agh, Maria Malmenas, Bryan Bennett</p>
PURPOSE	<p>To provide a discussion on the various methods used to estimate adherence to multiple medications (AtMM). Methods currently employed in the AtMM literature will be presented followed by a discussion of pros and cons of the methods and the calculations used to derive the measure of adherence.</p>
DESCRIPTION	<p>In a systematic review undertaken by the ISPOR Medication Adherence Special Interest Group identified 151 relevant studies on AtMM. Of these, 81 studies used a form of Morisky adherence scale and 54 used either the proportion of days covered (PDC) or medication possession ratio (MPR), each with varying methods to calculate AtMM. Other measures were also identified and several studies used multiple measures. This workshop will present the statistical methods and identify the different ways of deriving multiple medication adherence measures. . Discussion will be undertaken of whether the measurements affected the results and if there were measurements that provided more accurate results compared to the others. This will be followed by an audience interaction (15 minutes) on the advantages and disadvantages of using different identified methods and calculations. The concluding period will allow for wrap up, opportunities for questions and answers and examine recommendations for the next steps.</p>